PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 1-Year High at $48.96
PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $48.96 and last traded at $48.40, with a volume of 8089 shares traded. The stock had previously closed at $44.87.
纳斯达克(股票代码:PRCT-GET Rating)周四午盘交易中,普罗塞特生物机器人公司的股价创下52周新高。该股盘中一度涨至48.96美元,最新报48.4美元,成交量为8,089股。该股此前收盘报44.87美元。
Analyst Ratings Changes
分析师评级发生变化
PRCT has been the topic of a number of analyst reports. KeyCorp initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, July 15th. They issued an "overweight" rating and a $47.00 target price on the stock. B. Riley initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $53.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, September 2nd. They issued an "overweight" rating and a $49.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.50.
PRCT一直是许多分析师报告的主题。KeyCorp在7月15日星期五的一份研究报告中启动了对Procept BioRobotics股票的报道。他们对该股的评级为“增持”,目标价为47.00美元。B.莱利在6月23日星期四的一份研究报告中对Procept BioRobotics的股票进行了报道。他们对该股的评级为“买入”,目标价为53.00美元。最后,富国银行在9月2日星期五的一份研究报告中启动了对Procept BioRobotics股票的报道。他们对该股的评级为“增持”,目标价为49.00美元。一名分析师对该股的评级为持有,七名分析师对该公司的评级为买入。根据MarketBeat的数据,该公司目前的共识评级为“适度买入”,共识目标价为43.50美元。
PROCEPT BioRobotics Stock Performance
Procept BioRobotics股票表现
The stock has a market capitalization of $2.15 billion and a price-to-earnings ratio of -19.35. The company has a quick ratio of 15.27, a current ratio of 16.01 and a debt-to-equity ratio of 0.22. The stock's 50-day simple moving average is $38.53 and its 200 day simple moving average is $35.53.
该股市值21.5亿美元,市盈率为-19.35倍。该公司的速动比率为15.27,流动比率为16.01,债务权益比率为0.22。该股的50日简单移动均线切入位为38.53美元,200日简单移动均线切入位为35.53美元。
Insider Transactions at PROCEPT BioRobotics
Procept BioRobotics的内幕交易
In other news, Director Thomas M. Krummel sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total transaction of $719,600.00. Following the transaction, the director now directly owns 82,920 shares in the company, valued at $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.80% of the stock is owned by company insiders.
其他新闻方面,董事托马斯·M·克鲁梅尔在6月21日(星期二)的一笔交易中出售了2万股该公司股票。这些股票的平均价格为35.98美元,总成交额为719,600.00美元。交易完成后,董事现在直接拥有该公司82,920股,价值2,983,461.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在美国证券交易委员会网站上查阅。40.80%的股份由公司内部人士持有。
Hedge Funds Weigh In On PROCEPT BioRobotics
对冲基金参与Procept BioRobotics
A number of large investors have recently modified their holdings of the stock. US Bancorp DE acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $37,000. Amalgamated Bank acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $39,000. Shell Asset Management Co. acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $102,000. MetLife Investment Management LLC acquired a new position in PROCEPT BioRobotics in the first quarter valued at approximately $175,000. Finally, Quantbot Technologies LP acquired a new position in PROCEPT BioRobotics in the second quarter valued at approximately $178,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.
一些大型投资者最近调整了对该股的持有量。US Bancorp DE在第二季度收购了Procept BioRobotics的一个新头寸,价值约3.7万美元。合并银行在第一季度收购了Procept BioRobotics的一个新头寸,价值约3.9万美元。壳牌资产管理公司在第二季度收购了Procept BioRobotics的一个新头寸,价值约为102,000美元。大都会人寿投资管理公司在第一季度收购了Procept BioRobotics的一个新头寸,价值约为17.5万美元。最后,Quantbot Technologies LP在第二季度收购了Procept BioRobotics的一个新头寸,价值约为17.8万美元。76.23%的股票目前由机构投资者和对冲基金持有。
About PROCEPT BioRobotics
关于Procept BioRobotics
(Get Rating)
(获取评级)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Procept BioRobotics公司是一家外科机器人公司,开发泌尿外科变革性解决方案。该公司开发、制造和销售AquaBeam机器人系统,这是一种图像引导的外科机器人系统,用于治疗良性前列腺增生症(BPH)的微创泌尿外科手术。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- GameStop Stock Just Flashed A Buy Signal
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- 免费获取StockNews.com关于Procept BioRobotics(PRCT)的研究报告
- 安相能源有足够的动力继续提高动力吗?
- 独一无二的氢燃料电池库存
- 这两只被低估的股票已经做好了进一步冲高的准备
- GameStop股票刚刚闪烁了买入信号
- 化工和化肥库存中是否隐藏着宝藏?
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Procept BioRobotics日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Procept BioRobotics和相关公司的最新新闻和分析师评级的每日简要摘要。